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Background: Features of the tumor microenvironment influence the efficacy of cancer nanotherapeutics. The
ability to directly radiolabel nanotherapeutics offers a valuable translational tool to obtain biodistribution and tumor
deposition data, testing the hypothesis that the extent of delivery predicts therapeutic outcome. In support of a
first in-human clinical trial with 64Cu-labeled HER2-targeted liposomal doxorubicin (64Cu-MM-302), a preclinical
dosimetric analysis was performed.
Methods: Whole-body biodistribution and pharmacokinetic data were obtained in mice that received 64Cu-MM-302 and
used to estimate absorbed radiation doses in normal human organs. PET/CT imaging revealed non-uniform distribution
of 64Cu signal in mouse kidneys. Kidney micro-dosimetry analysis was performed in mice and squirrel monkeys, using a
physiologically based pharmacokinetic model to estimate the full dynamics of the 64Cu signal in monkeys.
Results: Organ-level dosimetric analysis of mice receiving 64Cu-MM-302 indicated that the heart was the organ receiving
the highest radiation absorbed dose, due to extended liposomal circulation. However, PET/CT imaging indicated that
64Cu-MM-302 administration resulted in heterogeneous exposure in the kidney, with a focus of 64Cu activity in the renal
pelvis. This result was reproduced in primates. Kidney micro-dosimetry analysis illustrated that the renal pelvis was the
maximum exposed tissue in mice and squirrel monkeys, due to the highly concentrated signal within the small
renal pelvis surface area.
Conclusions: This study was used to select a starting clinical radiation dose of 64Cu-MM-302 for PET/CT in
patients with advanced HER2-positive breast cancer. Organ-level dosimetry and kidney micro-dosimetry results
predicted that a radiation dose of 400 MBq of 64Cu-MM-302 should be acceptable in patients.
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Liposomal encapsulation fundamentally alters the behav-
ior of chemotherapeutics, enabling delivery of potent
cytotoxic drugs with an improved therapeutic index. The
large particle diameters of liposomes, typically 50 to
120 nm, coupled with varying levels of surface-bound
polyethylene glycol (PEG) to limit detection by the
mononuclear phagocyte system, result in particles with* Correspondence: dgaddy@merrimackpharma.com
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in any medium, provided the original work is pdramatically different in vivo behavior than small mol-
ecule therapeutics. It is understood that liposomes accu-
mulate in tissues with functionally porous vasculature,
such as the liver and spleen, as well as in tumors with
leaky vasculature, via the enhanced permeability and re-
tention (EPR) effect [1-3], while avoiding deposition in
tissues with tight endothelial barriers, such as the heart
[4]. By contrast, small molecules are passively distributed
in and out of almost all tissues in the body, contributing
to distinct safety and efficacy profiles.
MM-302 is a HER2-targeted liposomal doxorubicin
designed for selective uptake into HER2-overexpressingn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cells and tissues such as cardiomyocytes. MM-302 was
designed to build on PEGylated liposomal doxorubicin
(PLD) by retaining the improved cardiac safety profile of
PLD relative to conventional doxorubicin and improving
anti-tumor activity through immunotargeting of HER2.
The mechanism of action of MM-302 comprises de-
position of the nanoparticle in tumors with leaky vas-
culature through the EPR effect, followed by specific
targeting and uptake by HER2-overexpressing tumor
cells [4-6]. Preclinical studies have demonstrated im-
proved efficacy for MM-302 relative to untargeted PLD
[4,6] and quantitatively characterized the relationship
between HER2 antigen expression level and MM-302-
mediated doxorubicin delivery [5]. Importantly, the
conjugation of targeting moieties to liposomes has lit-
tle effect on gross biodistribution [6,7], provided that
the target is not expressed on vascular endothelial cells
or ubiquitously expressed in non-target tissues, and li-
posomal surface properties are not significantly al-
tered. MM-302 is currently in clinical development.
We hypothesize that for liposomal therapies, tumor
deposition is highly variable and a rate-limiting step for
effective drug delivery and anti-tumor activity [8]. The
extent to which liposomes accumulate within tumors is
governed by the inherent tumor physiology, as well as
the size and surface characteristics of the liposomes.
Vascular permeability is highly variable between different
tumor types, among patients with the same type of
tumor, and between distinct tumors within an individual
subject. Using 111In-diethylene triamine pentaacetic acid
(DTPA)-labeled PEGylated liposomes, Harrington et al.
demonstrated that liposome deposition varied from
undetectable to 53% ID/kg in patients [9]. Moreover, li-
posomal tumor deposition has been identified as a rate-
limiting step for drug delivery to tumor cells, supporting
the theory that deposition variability may directly result
in differential therapeutic response [8]. Correspondingly,
Arrieta et al. demonstrated that increased deposition of
99mTc-labeled PLD predicted response of mesothelioma
patients treated with PLD and cisplatin [10]. This is fur-
ther supported by preclinical studies showing a direct
correlation between variable liposome deposition in rat
xenograft models and tumor response to PLD [11].
These results suggest that identification of patients exhi-
biting increased tumor deposition may improve response
to nanotherapeutics.
We recently described the development of a gradient-
loadable chelator, diacetyl 4,4′-bis(3-(N,N-diethylamino)
propyl)thiosemicarbazone (4-DEAP-ATSC), as a means
to efficiently incorporate copper-64 (64Cu) into MM-302
[12]. In that work, we demonstrated that 64Cu remains
stably associated with the liposome following injection
into mice or incubation in human plasma. The ability todirectly and stably radiolabel nanotherapeutics such as
MM-302 offers the possibility of adapting these mole-
cules for combined therapy and diagnostic imaging and
provides a valuable translational tool to obtain quantita-
tive biodistribution and deposition data for therapeutic
agents. The current study leverages PET/CT imaging in
rodents and primates, in addition to traditional rodent
organ activity counts, to evaluate the biodistribution and
pharmacokinetics of 64Cu-MM-302 and estimate human
64Cu-MM-302 dosimetry. Results support the selection
of a starting radiation dose for a clinical study utilizing
64Cu-MM-302 with PET/CT in patients with advanced
breast cancer (NCT01304797). This approach offers po-
tential for evaluating the biodistribution of liposomal
agents and identifying patients most likely to respond to
nanotherapeutics.Methods
Liposome preparation
MM-302 was prepared as previously described [4,6].
MM-302 is a 100-nm liposome formulation composed
of hydrogenated soy phosphatidylcholine (HSPC; Lipoid,
Newark, NJ, USA), cholesterol, and 1,2-distearoyl-sn-gly-
cero-3-phosphoethanolamine-N-[amino(polyethylenegly-
col)-2000] (PEG-DSPE; Avanti Polar Lipids, Alabaster,
AL, USA) in a 3:2:0.3 molar ratio. Lipids were hydrated
with 250-mM ammonium sulfate, generating an electro-
chemical gradient for loading doxorubicin (2 mg/mL).
Anti-HER2 F5-PEG-DSPE conjugates were produced
and inserted into pre-formed, doxorubicin-loaded lipo-
somes, as previously described [13,14]. The extraliposomal
buffer was exchanged with 10-mM HEPES-buffered saline
(HBS, pH 6.5) via tangential flow filtration (Spectrum
Labs; Rancho Dominguez, CA, USA).64Cu chelation and liposome loading
The gradient-loadable 64Cu chelator, 4-DEAP-ATSC, has
been described previously [12]. 64CuCl2 was obtained
from the cyclotron facility at Washington University
School of Medicine (St. Louis, MO, USA). 64Cu, supplied
in 0.1 M HCl, was added to the 4-DEAP-ATSC solution
(12 MBq/nmol of 4-DEAP-ATSC). Chelation efficiency
was determined after 1 min incubation at room
temperature using instant thin layer chromatography
(ITLC) developed in 0.1 M citrate buffer (pH 6.0).
Under these conditions, unchelated free 64Cu travels
with the solvent front, while the chelated 64Cu:4-
DEAP-ATSC complex remains at the sample origin.
The ITLC strip was cut into two equal fractions, and
the radioactivity of each fraction was measured in a
gamma-counter (Perkin Elmer, Waltham, MA, USA).
This procedure yields chelation efficiencies consistently
greater than 98%.
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DEAP-ATSC (0.167 mol.% of phospholipid) was trans-
ferred to liposomes formulated in HEPES-buffered saline
solution (pH 6.5). The mixture was heated for 10 min at
65°C, then cooled in an ice water bath. Loading effi-
ciency was determined by size-exclusion chromatog-
raphy using illustra NICK columns (GE Healthcare
Biosciences, Pittsburgh, PA, USA). Importantly, loading
of 64Cu:4-DEAP-ATSC into liposomes had no effect on
the physiochemical properties of the liposomes [12].
Mouse studies
Mouse studies complied with Institutional Animal
Care and Use Committee guidelines. Female CD-1
mice were purchased from Charles River Laboratories
(Wilmington, MA, USA). Mice received intravenous
injections of 6 MBq of 64Cu-MM-302 in a volume of
200 L (n = 3 mice per time point). This corresponds to
20 mol/kg phospholipid or 3 mg/kg doxorubicin (drug
content basis). An additional mouse was injected and
housed separately for serial PET/CT imaging. At the
indicated times, mice were euthanized by isoflurane
inhalation followed by immediate cardiac puncture.
Tissues were collected and weighed, and their activities
assessed via gamma-counter. Radiopharmacokinetic pa-
rameters were estimated using MATLAB (TheMathworks,
Natick, MA, USA) and a non-compartmental model.
Absorbed radiation dose calculations
The time-integrated activity of each organ was calcu-
lated by integrating the area under the time-activity
curve using the trapezoidal method [15]. To estimate
mean absorbed doses in humans, the relative organ mass
scaling method was utilized. The mean absorbed dose in
each tissue was derived from the radionuclide concen-
tration, assuming a homogeneous distribution of the
radionuclide within any source region. The calculated
mean percentage injected dose per gram tissue (%ID/g)
for each organ in mice was extrapolated to determine


















Extrapolated percent injected activities in human or-
gans were fit with biexponential kinetic models and inte-
grated to estimate the number of disintegrations in
source organs. Radiation absorbed doses for each tissuewere calculated from the number of disintegrations
using OLINDA/EXM software (Vanderbilt University;
Nashville, TN, USA) [16].
Autoradiography
Female CD-1 mice (n = 2) were injected intravenously
with 6 MBq of 64Cu-MM-302. At 21 h post-injection,
mice were sacrificed and perfused with 20 mL PBS to re-
move vascular radioactivity. Both kidneys were collected
from each mouse, one dissected along the midline in the
coronal direction and the other in the axial direction.
Kidneys were fixed in OCT block and immediately proc-
essed for cryo-sectioning. Thirteen sections at 100 μm
were collected for each kidney for autoradiography.
Kidney sections on glass slides (without coverslip) were
placed against Super Resolution Storage Phosphor
Screens (Perkin Elmer, Waltham, MA, USA), separated
by a sheet of plastic wrap, and developed in a tight-
sealed cassette for 24 h. Autoradiography images were
acquired using Cyclone Plus Phosphor Imager and Opti-
quant software (Version 5.0; Perkin Elmer, Waltham,
MA, USA) at 600 dpi resolution.
Primate studies
All primate studies were carried out at MPI Research
(Mattawan, MI, USA), in compliance with guidelines
established by the United States Department of Agricul-
ture Institutional Animal Care and Use Committee. Two
female non-naïve squirrel monkeys were obtained from
the MPI Research stock colony. Animals were injected
intravenously via the saphenous vein with 37 to 55 MBq
of 64Cu-MM-302 in 5 mL, corresponding to 20 mol/kg
(phospholipid basis) or 3 mg/kg (doxorubicin basis).
Micro-PET/CT imaging
For image acquisition, mice were anesthetized using 2%
inhaled isoflurane and air mixture. PET data was ac-
quired on a microPET Focus 220 preclinical scanner
(Siemens; Malvern, PA, USA). At the center field of
view, the nominal acquisition resolution was 1.4 mm.
Static PET image acquisitions were performed consist-
ing of a 45-min emission scan immediately followed by
an 8-min transmission scan. The transmission scan,
used for attenuation and scatter correction, was ac-
quired using a rotating 57Co source. Data were recon-
structed using Siemen’s 3D ordered subset expectation
maximization and maximum a posteriori (OSEM3D/
MAP) algorithm with two iterations for OSEM3D and
18 iterations for MAP. The reconstructed image dataset
has a voxel size of 0.146 × 0.146 × 0.796 mm. To facili-
tate co-registration of the PET and CT datasets, mice
were kept on the same imaging bed (Equipment Veteri-
naire Minerve, Esternay, France) under anesthesia and
transported between the microPET and the microCT
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obtained on a Locus Ultra microCT preclinical scanner
(GE Healthcare; Pittsburgh, PA, USA) operating at 80
kVp and 50 mA. The images were reconstructed with
an isotropic voxel size of 0.154 mm. PET and CT images
were registered using Inveon Research Workplace
(IRW) software (Siemens; Malvern, PA, USA). Mice
remained under anesthesia for the duration of the PET
and CT image acquisitions (approximately 1 h total im-
aging time).
Primates were anesthetized with ketamine, and anesthesia
was maintained with 2% to 3% isoflurane in 100% oxygen.
PET images were obtained at 0 to 1 and 24 h (60-min scan
duration), followed immediately by CTscans. PET data were
acquired as 6 × 10 min continuous bed scans on a microPET
Focus 120 preclinical scanner (Siemens; Malvern, PA, USA)
equipped with PET detectors comprised of crystals of 1.5 ×
1.5 × 10 mm. Data were reconstructed using a 2D ordered
subset expectation maximization (OSEM2D) algorithm. The
reconstructed image dataset has a voxel size of 0.866 ×
0.866 × 0.796 mm. Animals were maintained on the same
bed under anesthesia for transfer between PET and CT in-
struments. Anatomical CTscans were obtained on a NanoS-
PECT/CT (Bioscan; Washington, DC, USA) at 80 kVp and
100 A. The images were reconstructed via filtered back-
projection with 0.442 × 0.442 × 0.442 mm voxel size. PET
and CT images were registered and quantified using Vivo-
Quant software (inviCRO; Boston, MA, USA). Animals
remained under anesthesia for the duration of the PET and
CT image acquisitions.
PET/CT image registration and analysis
Mouse PET/CT images were registered using a semi-
automated rigid image registration algorithm on an IRW
workstation. Regions of interest (ROIs) were drawn
manually on PET/CT slices in each organ and tissue of
interest. A linear interpolation algorithm was applied to
connect the ROIs to generate tissue volumes for quanti-
fication. CT data were used to generate contours in re-
gions with low PET signal or poor contrast with respect
to adjacent structures. Specifically for the renal pelvis
contours, where the spillover effect is present due to
high local 64Cu concentrations, ROIs were drawn based
on the PET signal only and the 64Cu-labeled liposome
uptake was quantified as %ID rather than %ID/g.
Primate PET data were registered to the corresponding
CT data using a rigid (rotation, translation) registration
with Mattes mutual information as the metric [17]. ROI
analysis was performed for the heart, kidneys, and renal
pelvis. Fixed-volume ellipsoid ROIs were positioned
within the heart and kidney regions. This approach was
chosen for these organs as they are relatively uniform in
size and shape and the use of fixed volume ROIs elimi-
nates variability in volume to produce more consistentconcentration estimates. Because of its more complex
shape and relatively higher variability, renal pelvis ROIs
were hand-drawn with a 3D ROI tool (VivoQuant,
inviCRO).
Kidney micro-dosimetry model
Kidney micro-dosimetry was performed using mouse
and primate images. The origin of the radioactive focus
was determined to be the renal pelvis. The radioactive
signal intensities of the entire kidney and renal pelvis
were determined from the signal in the left kidney and
scaled to reflect the signal in both kidneys, assuming
similar microdistribution. Based on autoradiography
and PET/CT images, the radioactive focus was exclu-
sively localized within the renal pelvis. The remaining
kidney signal was estimated to be uniformly distributed
across the other sub-regions (papillae, medulla, and
cortex). Time-activity curves were generated from five
imaging times (5 min, 2, 8, 21, and 43 h) for mice and
two imaging times (0 to 1, 24 h) for primates. Mouse
time-activity curves were scaled to human using the
organ-weight scaling method and published kidney
compartment sizes [18].
The first primate PET/CT image acquisition (0 to 1 h)
was binned into six frames of 10 min each to obtain in-
formation on early 64Cu-MM-302 pharmacodynamics. A
kinetic model was constructed to estimate the time-
activity curves in the primate kidney. The pharmacokin-
etics of 64Cu were assumed to be consistent with the be-
havior of MM-302 [4], following mono-exponential
kinetics, characterized by central (blood) compartment
volume, Vd, and elimination rate constant, kel. Blood
flow (Q) to the kidney transported 64Cu into the vascular
space of the kidney, the volume of which was character-
ized by the vascular volume fraction (VVF). Kidney
blood flow was assumed to be 5.5 mL/min/kg [19]. Kid-
ney volume was measured to be approximately 5 cm3,
based on CT analysis. 64Cu was assumed to deposit and
washout from the tissue space with first-order kinetics,
characterized by rate constants kin and kout, respect-
ively. From the tissue space, 64Cu can then accumulate
in the renal pelvis, characterized by first-order rate con-
stant, krpu. The renal pelvis volume was characterized
by the pelvis volume fraction (PVF). Renal pelvis accu-
mulation was assumed to be irreversible to enable a con-
servative absorbed radiation estimate of the contribution
from the renal pelvis. Data from the blood, total kidney,
and renal pelvis sub-region were used to simultaneously
fit Vd, kel, VVF, kin, kout, krpu, and PVF parameters, re-
spectively, to the data extracted from each set of primate
images using MATLAB Simbiology (The Mathworks,
Natick, MA, USA). Model equations and complete par-
ameter descriptions are included in (Additional file 1:
Table S1 and S2).
Table 1 Radiopharmacokinetic parameters of 64Cu-MM-302
Parameter Blood
t1/2 (h) 6.81 ± 0.58
Tmax (h) 1.00 ± 0.00
Cmax (%ID/g) 35.40 ± 1.86
CL (mL/h) 0.29 ± 0.01
Vss (mL) 2.96 ± 0.18
AUC(0−∞) (%ID/g*h) 347.90 ± 5.63
MRT(0−∞) (h) 10.31 ± 0.77
Abbreviations: t1/2 effective radioactive half-life, Tmax time to reach maximum
concentration, Cmax maximum concentration, CL clearance rate, Vss apparent
volume of distribution at steady state, AUC(0−∞) area under the time-activity
curve from 0 h to infinity, MRT mean residence time.
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Radiopharmacokinetics and biodistribution of
64Cu-MM-302 in mice
Radiopharmacokinetic data for 64Cu-MM-302 in naïve
female CD-1 mice (n = 3) are presented in Figure 1a.
Radiopharmacokinetic parameters were assessed using
non-decay corrected data and are summarized in Table 1.
The maximum radioactivity (Cmax) in the blood was
35.40 ± 1.86 %ID/g, with an effective 64Cu half-life (t1/2)
of 6.81 ± 0.58 h and a clearance rate (CL) of 0.29 ±
0.01 mL/h. Decay corrected data were also utilized to es-
timate pharmacokinetic parameters of MM-302 lipo-
somes, indicating a vascular t1/2 of 18.34 ± 2.90 h and
CL of 0.13 ± 0.02 mL/h (Additional file 2: Table S3).
These results are consistent with published properties of
PEGylated liposomes and previous studies measuring
the pharmacodynamics of MM-302 [4,20-23].
Complete biodistribution data for 64Cu-MM-302 is
presented in Additional file 2: Table S4. Most tissues
reached Cmax between 1 and 4 h post-injection. TheFigure 1 Radiopharmacokinetics of 64Cu-MM-302 in blood and maximum
blood (a), liver (b), spleen (c), kidneys (d), and lungs (e). Data represent the
decay corrected, representing 64Cu decay and 64Cu-MM-302 liposome kine
of injection, illustrating the pharmacokinetics of 64Cu-MM-302 liposomes.liver, spleen, kidneys, and lungs were the organs with
the greatest 64Cu-MM-302 accumulation. Time-activity
curves were derived from the biodistribution data and
are presented for the maximum exposed organs in
Figure 1b,c,d,e. Organ time-integrated activity coeffi-
cients, equivalent to the number of disintegrations perexposed organs of CD-1 mice. Data are expressed as %ID/g for the
mean ± SD of the three mice. Solid lines indicate data that are not
tics. Dashed lines represent data that are decay corrected to the time
Gaddy et al. EJNMMI Research  (2015) 5:24 Page 6 of 10unit radioactivity (MBq-h/MBq), were calculated using
the extrapolated values for human organs by integrating
the area under the time-activity curves. Radiation
absorbed-dose estimations for human tissues following
64Cu-MM-302 administration were determined using
OLINDA/EXM and are presented in Table 2. Due to the
long circulation time of 64Cu-MM-302, the heart was
the maximum exposed organ, with an absorbed dose of
0.525 mSv/MBq.
Mouse PET/CT imaging and kidney microdosimetry
The dosimetry calculations in Table 2 assume a homoge-
neous distribution of radionuclide within each organ. In-
spection of PET/CT images acquired from a mouse
injected with 64Cu-MM-302 (Figure 2a), however, indi-
cated a non-uniform distribution of the 64Cu signal
within the mouse kidney. All other organs demonstratedTable 2 Absorbed radiation dose estimates for
64Cu-MM-302




























EDE, effective dose equivalent; ED, effective dose.uniform signal distribution. Within the kidney, a focus
of 64Cu activity appeared in the center of the kidney at
early image acquisition times, peaking at 8 h post-
injection. Autoradiography studies confirmed the 64Cu
locus to be the renal pelvis (Additional file 3: Figure S1).
To determine the effect of renal pelvis radioactivity on
dosimetry estimations, micro-dosimetry analysis was
performed on the kidneys based on the MIRD pamphlet
no. 19 kidney micro-dosimetry model [18]. Figure 2b de-
picts time-activity curves of the total kidney and renal
pelvis generated from the PET/CT images at the indi-
cated time points for the mouse depicted in Figure 2a.
Human extrapolations were performed as described in the
‘Methods’ section, and radiation absorbed-dose estimates
for the kidney sub-regions are presented in Table 3.
Figure 2c summarizes the results of multiple inde-
pendent studies in which mice (n = 15) were imaged fol-
lowing injection with 64Cu-MM-302. The imaging times
were 18 to 24 h post-injection, with a median imaging
time of 21 h. It is interesting to note that renal pelvis ac-
cumulation was not a ubiquitous phenomenon following
64Cu-MM-302 treatment. Background renal pelvis signal,
indicating homogeneous distribution throughout the
kidney, was observed in 40% (6/15) of mice imaged,
while the mouse imaged during the dosimetry study
(Figure 2c, arrow) exhibited the highest levels.
Primate PET/CT imaging and kidney micro-dosimetry
The unexpectedly high levels of 64Cu accumulation in
the mouse renal pelvis following administration of 64Cu-
MM-302 led to additional kidney micro-dosimetry
studies in primates. Primate studies allowed the deter-
mination of whether renal pelvis accumulation may be
rodent-specific, and the larger primate physiology en-
abled more accurate kidney micro-dosimetry calcula-
tions. Primate PET/CT images were obtained at 0 to 1
and 24 h post-64Cu-MM-302 administration (Figure 3a).
The first PET/CT image was segmented into 10-min
windows of data to provide additional information on
early 64Cu-MM-302 pharmacokinetics. Intense 64Cu ac-
tivity was observed within the primate kidneys, with the
foci assumed to exclusively represent the renal pelvis
and the remaining signal uniformly distributed across
the other kidney sub-regions. Time-activity curves of the
total kidney and renal pelvis were generated from the
primate PET/CT images (Figure 3b).
Due to the limited number of primate imaging time
points, it was necessary to construct a kinetic model
(Figure 3c) to estimate the full dynamics of 64Cu uptake
in the renal pelvis for accurate estimation of radiation
absorbed dose. The model assumed that radioactivity
from the blood served as the driving source for accumu-
lation of 64Cu in the kidney. 64Cu (presumably liposo-
mal, due to absence of bladder signal (Figures 2a and 3a
Figure 2 Rodent PET/CT imaging and kidney micro-dosimetry. (a) Maximum intensity projection (MIP) PET imaging time-course of a mouse
treated with 64Cu-MM-302. Data are not decay corrected. (b) Time-activity curves of the total kidney (squares) and renal pelvis (circles) generated
from the mouse PET images. Data are not decay corrected. (c) Comparison of %ID/g in the total kidney and renal pelvis from mice treated with
64Cu-MM-302 in independent imaging studies. Each data point represents an individual mouse (n = 15). Lines indicate the mean ± SD. The arrow
denotes the mouse imaged during the 64Cu-MM-302 dosimetry study. Data are decay corrected to the time of injection.
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of the kidney tissue space with first-order kinetics, and a
portion of the tissue-deposited 64Cu may then accumu-
late in the renal pelvis. Renal pelvis uptake was assumed
to be irreversible to enable a conservative absorbed radi-
ation estimate of the contribution from the renal pelvis.
Figure 3d illustrates predicted blood pharmacokinetics
of 64Cu-MM-302 and indicates a t1/2 of 20 h for MM-
302 liposomes in primates. Figure 3e illustrates the pre-
dicted kinetics of 64Cu accumulation in the total kidney
and renal pelvis. Rather than use organ-weight scaling,
the model enabled a physiologically based scale-up to
predict human time-activity curves and time-integrated
activity coefficients. The following model parameters
were changed to reflect human-based values: Vd wasTable 3 Absorbed radiation dose estimates for 64Cu-MM-302









Total kidney 0.07 0.17changed to 4.8 L, kel was changed to 0.000467 L/min
(based on 53 h t1/2 for PLD) and kidney volume changed
to 310 g [24]. Radiation absorbed doses for the kidney
sub-regions were calculated using published S-values
[18] and are presented in Table 3.
Discussion
We recently reported a method to stably label pre-formed,
drug-loaded liposomes with 64Cu, providing the opportun-
ity to utilize PET imaging to quantify biodistribution of
nanotherapeutics [12]. In the current work, the biodistri-
bution and pharmacokinetics of 64Cu-MM-302 were in-
vestigated in mice and extrapolated to estimate human
dosimetry. Biodistribution was consistent with previously
published data, and organ-level dosimetry indicated that
the maximum exposed organs were the heart and kidneys,
with estimated radiation absorbed doses of 0.525 mSv/MBq
and 0.067 mSv/MBq, respectively.
Inspection of mouse PET/CT images revealed a small
subregion of high 64Cu activity in the renal pelvis. This ob-
servation prompted micro-dosimetric evaluation based on
imaging data, which measured an absorbed radiation dose
of 0.610 mSv/MBq to the renal pelvis. These values were
confirmed by analysis of primate imaging data, wherein
the estimated absorbed radiation dose to the renal pelvis
was 0.650 mSv/MBq.
Figure 3 Primate PET/CT imaging and kidney micro-dosimetry. (a) MIP PET imaging time-course of a squirrel monkey treated with 64Cu-MM-302.
Data from 0- to 1-h time-point was segmented into 10-min windows. (b) Time-activity curves of the total kidney (filled circles) and renal pelvis
(open circles) generated from the primate PET/CT images. (c) Schematic representing the physiologically based pharmacokinetic model that was
utilized to estimate the full dynamics of 64Cu signal from primate images. (d) Predicted blood pharmacokinetics of 64Cu-MM-302 based on data
obtained at the imaging time points (red circles) fit to the primate pharmacokinetic model (red line). (e) Predicted kinetics of 64Cu accumulation
based on data obtained in the total kidney (black circles) and renal pelvis (yellow circles) fit to the primate model for the total kidney (black line)
and renal pelvis (yellow line). The inset illustrates accumulation of 64Cu signal in the total kidney over the 0- to 1-h imaging time, with each point
representing one of the 10-min windows. All data are decay corrected to the time of injection.
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delivery to tumors and tissues have previously been de-
veloped for PLD and MM-302 [4,8]. Here, we developed
and applied a similar kinetic modeling approach to esti-
mate the time-course of 64Cu uptake in the total kidney
and renal pelvis from the limited set of primate data.
Primate micro-dosimetry calculations confirmed mouse
data, predicting the renal pelvis to be the maximum ex-
posed kidney sub-region. The model took advantage ofknown physiological constraints in estimating the time-
course of uptake, namely that 64Cu should be delivered
from the blood. As such, the model took into account
the diminishing driving force for kidney deposition as
64Cu cleared from the bloodstream over time. Further,
the model assumed irreversible deposition of 64Cu in
the renal pelvis, likely resulting in conservative radi-
ation absorbed-dose estimates. Finally, the model en-
abled physiologically based scaling to human behavior
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weight scaling. Expansion of this modeling approach to all
organ systems might further improve the ability of precli-
nical data to accurately predict clinical results. Retrospec-
tive analyses would be needed to confirm this hypothesis.
The accumulation of 64Cu radioactivity in the renal pel-
vis was a relatively low fraction of overall administered ac-
tivity (<2%ID) and, although concentrated in a small area,
would not be expected to cause safety concerns. Addition-
ally, the renal pelvis accumulation does not appear to
affect levels of deposition in other tissues. While intense
kidney signal is not typical of radiolabeled liposomes
[25,26], a similar phenomenon has previously been noted
in rats treated with 186Re-PLD and 186Re-PEG-liposomes
[27], as well as 99mTc-PLD [28]. Importantly, no accumu-
lation of doxorubicin has been observed in the renal pelvis
(unpublished data), further reducing the risk of renal
toxicity. With a diameter of approximately 100 nm, the
MM-302 liposome is significantly larger than a molecule
capable of glomerular filtration [29]. The renal pelvis
signal is unlikely to be the result of 64Cu pooling in the ur-
eter, as the signal increases relative to background over
the 43-h imaging time course, with no significant increase
in bladder signal or urine excretion (Figures 2a and 3a,
Additional file 2: Table S4 and unpublished data). Mouse
studies have demonstrated that >94% of 64Cu remains
MM-302-associated after 24-h post-injection [12]. This
might suggest that 64Cu released during clearance of
64Cu-MM-302 has affinity for the renal pelvis. However,
imaging studies with free 64Cu and 64Cu:4-DEAP-ATSC,
as well as 64Cu:4-DEAP-ATSC-labeled nanoliposomal iri-
notecan (64Cu-nal-IRI) have revealed uniform kidney dis-
tribution (unpublished data), further suggesting that renal
pelvis accumulation is not driven by the chelator.
Biodistribution of 64Cu-MM-302 was similar to pub-
lished data on 64Cu-DOTA-labeled PEGylated liposomes
[25] and 111In-DTPA-labeled PEGylated liposomes in
mice [26]. The consistent biodistribution profiles of radi-
olabeled liposomes suggests that this data may also be
used to provide first-order estimates of the radiation
absorbed doses for liposomes stably labeled with other ra-
dioisotopes. Moreover, while additional factors such as
spatial resolution and method of labeling must be consid-
ered, such first-order dosimetry estimates may be used to
aid identification of optimal isotopes for specific imaging
purposes. An example comparison of the liver absorbed-
dose estimates for a variety of PET and SPECT isotopes,
extrapolated from 64Cu-MM-302 mouse dosimetry data,
is presented in Additional file 4: Table S5 and suggests
that, with regard to organ dosimetry, 64Cu is the preferred
PET radioisotope for labeling long-circulating liposomes.
Results presented here support the radioactive dose selec-
tion of 64Cu-MM-302 for clinical studies and illustrate the
potential of combining nanotherapeutics with diagnosticimaging. For a proposed starting administered activity of
400 MBq, our analyses predict a radiation dose to the renal
pelvis of approximately 250 mSv (25 cGy). These values
are in the range of radiation doses reported for several
approved radiopharmaceutical agents (Additional file 4:
Table S6). 64Cu-MM-302 is currently being studied in pa-
tients with advanced breast cancer (NCT01304797).
This work represents a step in the development of a lipo-
somal imaging agent for identifying patients with a clinic-
ally favorable biodistribution and tumor deposition profile
that would be likely to respond to liposomal therapy. A
non-therapeutic imaging agent would have the additional
advantage of sparing patients harmful side-effects of
chemotherapy-containing liposomes during the treatment
planning phase. As such, we are currently developing a
drug-free 64Cu-liposomal PET agent that could potentially
be implemented as a companion diagnostic to prospectively
select patients for liposomal nanotherapeutics.
Conclusions
Here, we present murine whole-body biodistribution and
pharmacokinetics of 64Cu-MM-302, as well as rodent and
primate kidney micro-dosimetry, with biodistribution data
extrapolated to predict human 64Cu-MM-302 dosimetry.
Organ-level and kidney micro-dosimetry estimates in ro-
dents and primates support a proposed starting adminis-
tered activity of 400 MBq of 64Cu-MM-302 for clinical
imaging studies in patients with advanced HER2-positive
breast cancer (NCT01304797). Clinical translation of
64Cu-MM-302 PET/CT imaging will determine the extent
to which liposomal tumor deposition is predictive of pa-
tient response and potentially pave the way for liposome-
based imaging diagnostic strategies.
Additional files
Additional file 1: Model equations and complete parameter
descriptions. Table S1. Equations for kinetic model of 64Cu signal in the
kidney arising from liposomal 64Cu. Table S2. Kinetic model parameter
descriptions.
Additional file 2: Table S3. Pharmacokinetic parameters of MM-302
liposomes. Table S4. Biodistribution of 64Cu-MM-302 in CD-1 mice.
Additional file 3: Figure S1. Autoradiography was performed to
qualitatively measure relative 64Cu intensity in mouse kidney sections.
The left image indicates the transversal slice and the right image indicates the
coronal slice.
Additional file 4: Comparison of isotopes useful for radiolabeling
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